相关临床试验
510
50 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2011
进行中（未招募）
49
9.6%
已完成
373
73.1%
尚未招募
1
0.2%
招募中
27
5.3%
暂停
2
0.4%
终止
35
6.9%
Unknown
7
1.4%
撤回
16
3.1%
暂无批准数据
- The Alliance for Clinical Trials in Oncology has activated the QUANTUM Trial (Alliance A062401), a Phase II study testing the bispecific antibody teclistamab as post-transplant consolidation in newly diagnosed primary plasma cell leukemia. - Primary plasma cell leukemia is a rare and aggressive blood cancer with approximately 1,200 new U.S. cases annually, and long-term survival remains poor despite intensive modern therapy. - The trial will randomize 74 adults after autologous stem cell transplant to receive either teclistamab consolidation or continued D-KRd quadruplet therapy, with overall survival as the key endpoint. - Teclistamab, already FDA-approved for certain multiple myeloma patients, is a BCMA×CD3 bispecific antibody that redirects T cells to attack malignant plasma cells, and this study will determine whether earlier use can improve long-term outcomes.
- A pilot study of the Participant Engagement Portal (PEP) found that 84% of cancer clinical trial participants reported a positive experience using the digital tool. - The portal achieved 96% ease-of-access ratings and 93% survey completion ease, with 93% of users agreeing to be contacted for future research. - PEP successfully gathered social determinants of health data, with 100% of respondents providing zip codes and 94% disclosing ancestry or ethnic origin. - Community clinics outperformed academic medical centers in patient enrollment, though researchers noted the need for greater demographic diversity in future iterations.
- CABOMETYX demonstrated significant improvements in progression-free survival for patients with previously treated advanced neuroendocrine tumors regardless of functional status in the phase 3 CABINET trial. - The drug reduced the risk of disease progression or death by 74% in non-functional NET and 60% in functional NET compared to placebo. - Median progression-free survival increased threefold in non-functional NET (9.4 vs 3.1 months) and more than doubled in functional NET (12.7 vs 5.4 months) compared to placebo. - The safety profile remained consistent with known CABOMETYX adverse events, with hypertension being the most frequent grade 3/4 adverse event in both patient groups.
- The Alliance A221805 trial found that duloxetine, an antidepressant commonly used to treat chronic pain, does not prevent nerve damage caused by oxaliplatin chemotherapy in colorectal cancer patients. - The randomized, double-blind, placebo-controlled trial enrolled 199 patients across 73 cancer centers and tested two duloxetine doses (30mg and 60mg daily) against placebo for 17 weeks. - Response rates were similar across all groups (65.2% for 30mg duloxetine, 66% for 60mg duloxetine, and 68% for placebo), showing no statistically or clinically meaningful difference. - The findings confirm that while duloxetine remains effective for treating established chemotherapy-induced neuropathy, it should not be used for prevention purposes.
- A Phase II randomized, double-blind, placebo-controlled trial found that oxybutynin, commonly used for overactive bladder, significantly reduces hot flashes in men receiving androgen-deprivation therapy for prostate cancer. - The study showed dose-dependent improvements, with the 5 mg twice daily group experiencing 6.89 fewer hot flashes per day and a 13.95-point reduction in severity scores compared to placebo. - Seventy-nine percent of patients receiving the higher dose achieved at least a 50% reduction in hot flash scores, compared to only 32% in the placebo group. - The treatment was well-tolerated with dry mouth as the most common side effect, offering a new therapeutic option for managing this challenging side effect that affects up to 80% of men on hormone therapy.
- A national clinical trial led by Mass General Brigham found that abemaciclib, an oral CDK inhibitor, may slow tumor growth in patients with aggressive meningiomas carrying NF2 mutations or CDK pathway alterations. - Among the first 24 patients treated, 58% had high-grade tumors that didn't progress within six months, comparing favorably to historical controls of 0-29% progression-free survival at six months. - The study achieved a median progression-free survival of 10 months and median overall survival of 29 months, with manageable side effects similar to those seen in breast cancer patients. - This represents the first national genomically-driven trial for meningioma patients, demonstrating the feasibility of targeted therapy approaches for this understudied population.
- A blood test measuring circulating tumor DNA (ctDNA) can identify stage III colon cancer patients who benefit from adding celecoxib to standard chemotherapy after surgery. - Patients testing positive for ctDNA after surgery who received celecoxib showed nearly doubled disease-free survival at three years (41% vs 22.6%) compared to placebo. - The findings from the CALGB/SWOG 80702 trial involving 940 patients could enable personalized treatment decisions and avoid unnecessary medication for patients unlikely to benefit. - ctDNA-negative patients showed no significant survival benefit from celecoxib, maintaining favorable outcomes regardless of treatment assignment with five-year survival exceeding 91%.
- A phase II clinical trial demonstrated that combining avelumab and cetuximab nearly quadrupled median progression-free survival compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma. - The combination therapy achieved a median progression-free survival of 11.1 months versus 3.0 months for avelumab monotherapy, with a hazard ratio of 0.48 and statistical significance. - The study enrolled 57 evaluable patients with advanced cSCC, showing that dual immunotherapy targeting both PD-L1 and EGFR pathways creates synergistic anti-tumor effects. - Results provide valuable insights for future trials combining standard-of-care immunotherapies with cetuximab to improve outcomes in this aggressive skin cancer.
- Leading oncologists discuss the current limitations of circulating tumor DNA (ctDNA) testing in muscle-invasive bladder cancer, highlighting the need for more evidence before routine clinical implementation. - The IMvigor011 trial is exploring ctDNA's potential to guide immunotherapy decisions, with experts suggesting its greatest value may lie in predicting treatment response rather than early detection. - While some clinicians use Signatera ctDNA testing between scans, experts caution against replacing standard imaging without stronger evidence of improved patient outcomes.
- The PROSPECT-Lung trial is evaluating whether immunotherapy is more effective when administered before or after surgery for resectable non-small cell lung cancer. - This pragmatic trial aims to reflect real-world treatment decisions and provide clearer guidance on integrating immunotherapy into lung cancer treatment regimens. - The study will enroll 1,100 patients across multiple sites in the United States and is led by the Alliance for Clinical Trials in Oncology and the SWOG Cancer Research Network. - PROSPECT-Lung is the first trial to open through the NCI's Clinical Trials Innovation Unit, designed to accelerate cancer treatment development.
